Knowledge at the heart of leadership
Welcome to Liftstream - Life Sciences Recruitment

Liftstream is an executive search recruitment company in the life sciences sector

Editas Medicine Appoints John D. Mendlein to Board of Directors

Editas Medicine, a genome editing company based in Cambridge, Mass, has appointed John D. Mendlein to its board of directors. Mendlein has served as CEO of aTyr Pharma since 2011, as well as executive chairman for the company from July … Continue reading

Posted in Board Director Appointments | Tagged , , , , , , , , , | Leave a comment

China’s Simcere Plans Hong Kong IPO

Simcere Pharmaceutical Group, based in Jiangsu province, China, is preparing to raise as much as USD1 billion in a Hong Kong IPO in the third quarter, according to The Wall Street Journal. The firm did not release any official statement … Continue reading

Posted in General | Tagged | Leave a comment

Kite Pharma Shows Positive results from non-Hodgkin lymphoma study

Authored by James Sheppard The California based biotech company Kite Pharma announced that it has achieved positive clinical data from its non-Hodgkin’s lymphoma treatment, KTE-C19, the company’s leading drug candidate. KTE-C19 is being developed for use in patients with diffuse … Continue reading

Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , | Leave a comment

Avalanche Biotechnologies raises $102m in up-sized IPO

Authored by James Sheppard The California based gene therapy company Avalanche Biotechnologies announced that it has raised $102m from its initial public offering (IPO). The company will be listed on the NASDAQ under the ticker symbol AAVL. Avalanche develops gene … Continue reading

Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , | Leave a comment

Rare Disease biotech Aldeyra raises $25m in IPO

Authored by James Sheppard The Boston biotech cluster based company Aldeyra Therapeutics have raised $25m in an oversubscribed initial public offering (IPO). Aldeyra Therapeutics are developing treatments for rare skin and eye diseases. The clinical stage biotech company’s lead candidate … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases | Tagged , , , , , , , , , , , | Leave a comment

BioBlast founders ramp towards another IPO for rare disease company

Authored by Karl Simpson BioBlast Pharma is another rare disease therapeutics company shaping up for an IPO. The Israeli start-up is developing drug therapies for Oculopharyngeal Muscular Dystrophy (OMPD), Machado Joseph Disease and Kennedy’s disease. The company’s lead product is … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases | Tagged , , , , , , , , , , | Leave a comment

Ultragenyx follows IPO with Board Appointments

Authored by Karl Simpson It has been a big week for Ultragenyx, the ultra-rare diseases company focused on metabolic genetic disorders. Last Friday they listed on Nasdaq under the ticker “RARE” in an initial public offering of 6,624,423 shares of … Continue reading

Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , | Leave a comment

Dr Michael Pellini – Foundation Medicine – Executive Leadership Series

Authored by Karl Simpson At the beginning of 2013 Liftstream profiled 13 life science leaders we believed were going to make an impact over the course of the year. Below we outline how Dr Michael Pellini performed for Foundation Medicine in 2013. 2013 Liftstream Analysis: Dr. … Continue reading

Posted in Pharmaceutical business | Tagged , , , , , , , , , , | Leave a comment

CFO appointments no longer just a numbers game

Authored by Karl Simpson AstraZeneca’s CEO, Pascal Soriot, recently said when announcing the newly appointed CFO Marc Dunoyer that he offered a blend of strategic thinking and financial expertise. Mr. Dunoyer joined AstraZeneca earlier this year from GSK where he … Continue reading

Posted in General, Pharmaceutical business, Recruitment Market | Tagged , , , , , , , , , , , , , , , , , , , , | Leave a comment

Prosensa, Sarepta, PTC, Summit and DART all contribute to the ubiquity of news in Duchenne

Authored by James Sheppard The Duchenne Muscular Dystrophy market has seen considerable advances  in recent months, with companies Prosensa, PTC Therapeutics, Sarepta Therapeutics, Summit and considerable others announcing regular news on  funding, IPOs, research, clinical and regulatory. Prosensa, the Dutch … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | 2 Comments




Contact Us

   Liftstream Ltd.
67 Grosvenor Street
London
W1K 3JN

   Tel: ​+44 (0)20 3178 5864
   info@liftstream.com

Register your CV

Apply for sector specific vacancies or request a confidential discussion



Registered in England No: 5009233
VAT: 843679292

Follow Us





Sitemap